[SNY] Sanofi Thesis 2026: Dupixent Franchise Drives Post-Consumer Health Spinoff Cycle

Key Takeaways

• Sanofi SA (NASDAQ: SNY) FY2025 revenue ~€42-44B (+5-9% YoY) with business EPS ~€7.20-7.80 reflecting continued Dupixent (dupilumab) ~€13-14B revenue (30% revenue mix; +20%+ growth) plus selected post-October 2024 Opella consumer healthcare spin-off completion (€16B aggregate transaction value via CD&R 50% stake purchase) plus refocus on biopharma + vaccines under continued CEO Paul Hudson (~6-year tenure since September 2019; ex-Novartis Pharmaceuticals President 2016-2019 + ~30-year pharma career; succeeded Olivier Brandicourt 2015-September 2019 retired who led Sanofi through Genzyme integration).
• Dupixent franchise leadership: ~€13-14B revenue FY2025 (~30% revenue mix); selected post-2024 expansion into 6th major indication (COPD with type 2 inflammation September 2024); current 6 major indications include atopic dermatitis (2017) + asthma (2018) + chronic rhinosinusitis with nasal polyposis (2019) + eosinophilic esophagitis (2022) + prurigo nodularis (2022) + COPD with type 2 inflammation (September 2024); selected ~50-50 profit share with Regeneron; Dupixent on track toward ~€20B+ peak sales potential.
• Opella consumer healthcare spin-off: October 2024 announced ~€16B aggregate transaction value spin-off to CD&R (CD&R purchasing 50% stake; Sanofi retaining 48% + ~2% retained employee shares); selected ~€8B+ proceeds to Sanofi for refocused biopharma + vaccines strategy; selected expected close H1 2025 followed by Sanofi accelerated buyback + selected various capital deployment.
• Capital return: €3.92-4.02 annual dividend FY2025 (+1-3% growth post-2024 €3.92; ~30+ year continuous track); ~€5B aggregate FY2024-2025 buybacks (post-October 2024 Opella spin-off proceeds deployment); investment-grade A1/AA credit rating; selected post-Opella spin-off net cash position ~€5-7B.

Company Background

Sanofi SA (NASDAQ: SNY) is a global biopharmaceutical leader with FY2025 revenue ~€42-44B (+5-9% YoY) and business EPS ~€7.20-7.80 reflecting continued Dupixent (dupilumab) franchise leadership ~€13-14B revenue, selected post-October 2024 Opella consumer healthcare spin-off completion, and refocus on biopharma + vaccines. The company employs ~91,000+ globally with operations across pharmaceuticals + vaccines + selected continued consumer healthcare (~48% retained Opella stake) in ~100+ countries.

Founded 1973 as Sanofi via Société Nationale Elf Aquitaine pharmaceuticals subsidiary creation; selected post-1999 ~$30B Sanofi-Synthélabo merger; selected post-August 2004 ~$66B Aventis acquisition creating Sanofi-Aventis; selected post-2009 rebranding back to Sanofi; selected post-April 2011 ~$20B Genzyme acquisition (rare diseases + multiple sclerosis); selected post-2018 ~$11B Bioverativ acquisition (hemophilia); selected post-2018 ~$4.8B Ablynx acquisition; selected post-2020 ~$3.7B Principia Biopharma acquisition (autoimmune); selected post-2020 $3.4B Translate Bio mRNA acquisition; selected post-October 2024 Opella consumer healthcare spin-off announcement (€16B aggregate transaction value).

Headquartered in Paris France; ~91,000+ employees globally with ~€42-44B revenue. Three primary reporting segments: Pharmaceuticals 75% revenue (€32B — Specialty Care including Dupixent + immunology + rare diseases + multiple sclerosis + oncology; General Medicines including Lantus + Toujeo diabetes + cardiovascular + selected other), Vaccines 15% (€6-7B — influenza Fluzone + Beyfortus RSV + Adacel pertussis + Menquadfi meningococcal + selected travel + endemic vaccines), Consumer Healthcare (Opella) 10% (€5B — selected post-October 2024 spin-off retained ~48%; products include Allegra + Doliprane + selected over-the-counter analgesics).

CEO Paul Hudson since September 2019 (~6-year tenure); succeeded Olivier Brandicourt (CEO 2015-September 2019 retired who led Sanofi through Genzyme integration); Hudson ex-Novartis Pharmaceuticals President 2016-2019 + ex-AstraZeneca Specialty Care VP North America 2013-2016 + ~30-year pharma career; British nationality; selected continued strategic priorities include Dupixent franchise expansion + immunology pipeline + Opella spin-off completion + selected portfolio simplification.

Dupixent Franchise Leadership

Dupixent (dupilumab; IL-4Rα inhibitor) franchise represents selected primary growth driver:

• FY2025 revenue: ~€13-14B (+20%+ YoY; ~30% revenue mix)
• Indications: 6 major indications: atopic dermatitis (2017) + asthma (2018) + CRS with nasal polyposis (2019) + eosinophilic esophagitis (2022) + prurigo nodularis (2022) + COPD with type 2 inflammation (September 2024 FDA approval)
• Profit share: ~50-50 with Regeneron (originating partner)
• Peak sales potential: ~€20B+ aggregate (Sanofi share ~€10B+)
• FY2026 expansion: continued indication expansion + bullous pemphigoid + chronic spontaneous urticaria pivotal trials

FY2026 catalyst: continued Dupixent revenue growth ~+15-18% + ~€2.5-3B incremental revenue + ~€0.30-0.50 incremental EPS contribution.

Opella Consumer Healthcare Spin-Off

Post-October 2024 announced ~€16B aggregate transaction value Opella consumer healthcare spin-off:

• Transaction structure: CD&R purchasing 50% Opella stake at ~€16B aggregate enterprise value; Sanofi retaining 48% + ~2% retained employee shares
• Proceeds to Sanofi: ~€8B+ aggregate (~50% Opella enterprise value)
• Expected close: H1 2025 (subject to regulatory + customary closing conditions)
• Strategic rationale: refocus on biopharma + vaccines; Opella standalone capital allocation flexibility
• Capital deployment: post-close Sanofi accelerated buyback + selected various capital deployment

FY2026 catalyst: Opella spin-off close + ~€8B proceeds deployment + accelerated buyback + ~€2-3B incremental FY2025-2026 buyback.

Vaccines + Beyfortus RSV

Sanofi vaccines business 15% revenue (€6-7B) covers:

• Influenza Fluzone: ~€3B+ revenue; selected market leader US + Europe seasonal influenza
• Beyfortus (nirsevimab) RSV: ~€1-2B revenue FY2025 (vs ~€1.7B FY2024); ~50-50 profit share with AstraZeneca; FDA approved July 2023 for infant RSV prevention; ~70-80% US RSV prevention market share
• Adacel pertussis + Menquadfi meningococcal + selected travel + endemic vaccines: ~€2-3B aggregate

FY2026 catalyst: continued Beyfortus RSV growth + flu vaccine + selected pipeline development + ~€0.10-0.20 incremental EPS contribution.

Risks

• Dupixent biosimilar erosion: Dupixent loss of exclusivity ~2031 patent expiry; selected biosimilar competition long-term risk
• Pipeline failures: late-stage pipeline including itepekimab COPD + Tolebrutinib MS + selected various Phase 3 trials
• Vaccines competition: Beyfortus RSV competition from Pfizer Abrysvo + GSK Arexvy
• Macro pricing: US Inflation Reduction Act Medicare drug price negotiation + EU pricing pressure
• Opella spin-off execution: regulatory + tax + operational separation milestones

Key Core Metrics

Market Evaluation

Sanofi trades at selected ~14-16x FY2026 business P/E discount vs Eli Lilly (~30-40x) + Novo Nordisk (~25-30x) + Pfizer (~13-15x) reflecting selected pre-Opella spin-off conglomerate discount + selected Dupixent ~30% revenue concentration + selected ~2031 Dupixent loss of exclusivity overhang. Selected re-rating catalysts include: (1) continued Dupixent franchise growth ~+15-18% sustaining; (2) Opella spin-off close + ~€8B proceeds deployment; (3) accelerated buyback execution; (4) immunology pipeline progression including itepekimab COPD + Tolebrutinib MS; (5) Beyfortus RSV continued growth.

Dupixent Franchise Indication Expansion Deep Dive

Dupixent (dupilumab; IL-4Rα inhibitor) franchise represents selected single largest growth driver in Sanofi portfolio with ~€13-14B FY2025 revenue (~30% revenue mix; +20%+ YoY growth). Dupixent's ~50-50 profit share with Regeneron (originating partner) generates ~€6.5-7B annual Sanofi share with selected continued indication expansion driving long-term growth toward ~€20B+ aggregate peak sales potential. Dupixent currently approved across 6 major indications including atopic dermatitis (2017) + asthma (2018) + chronic rhinosinusitis with nasal polyposis (2019) + eosinophilic esophagitis (2022) + prurigo nodularis (2022) + COPD with type 2 inflammation (September 2024 FDA approval representing first biologic approved for COPD globally). Selected pipeline indications include bullous pemphigoid Phase 3 (PDUFA 2025) + chronic spontaneous urticaria Phase 3 (PDUFA 2025) + selected various Phase 2/3 indications. FY2026 catalyst: continued Dupixent revenue growth ~+15-18% + ~€2.5-3B incremental revenue + ~€0.30-0.50 incremental EPS contribution.

FY2026 thesis: Dupixent franchise expansion + Opella spin-off close + accelerated buyback + immunology pipeline + Beyfortus RSV growth.